Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA033989 Versus Best Available Therapy in Essential Thrombocythemia (EXCALIBUR-ET2)
NCT07623200Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Countries
- 22
01
Overview
A Phase 3 trial of inca033989 in essential thrombocythemia (ET), sponsored by Incyte. Started Sep 2026; status: recruiting.
02
Drugs
inca033989
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT07623200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623200.